GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pharmigene Inc (ROCO:7595) » Definitions » EV-to-FCF

Pharmigene (ROCO:7595) EV-to-FCF : -1.67 (As of Jun. 09, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Pharmigene EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharmigene's Enterprise Value is NT$1,244.7 Mil. Pharmigene's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-745.3 Mil. Therefore, Pharmigene's EV-to-FCF for today is -1.67.

The historical rank and industry rank for Pharmigene's EV-to-FCF or its related term are showing as below:

ROCO:7595' s EV-to-FCF Range Over the Past 10 Years
Min: -32.48   Med: -20.07   Max: -1.58
Current: -1.69

During the past 7 years, the highest EV-to-FCF of Pharmigene was -1.58. The lowest was -32.48. And the median was -20.07.

ROCO:7595's EV-to-FCF is ranked worse than
100% of 89 companies
in the Medical Diagnostics & Research industry
Industry Median: 25.5 vs ROCO:7595: -1.69

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-09), Pharmigene's stock price is NT$16.95. Pharmigene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-1.600. Therefore, Pharmigene's PE Ratio for today is At Loss.


Pharmigene EV-to-FCF Historical Data

The historical data trend for Pharmigene's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmigene EV-to-FCF Chart

Pharmigene Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - -36.87 -18.59 -19.36 -1.92

Pharmigene Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.59 - -19.36 - -1.92

Competitive Comparison of Pharmigene's EV-to-FCF

For the Diagnostics & Research subindustry, Pharmigene's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmigene's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pharmigene's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharmigene's EV-to-FCF falls into.



Pharmigene EV-to-FCF Calculation

Pharmigene's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1244.722/-745.348
=-1.67

Pharmigene's current Enterprise Value is NT$1,244.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmigene's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-745.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmigene  (ROCO:7595) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pharmigene's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=16.95/-1.600
=At Loss

Pharmigene's share price for today is NT$16.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmigene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-1.600.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pharmigene EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharmigene's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmigene (ROCO:7595) Business Description

Traded in Other Exchanges
N/A
Address
No. 101 Ruihu Street, 5th Floor, Neihu District, Taipei, TWN, 11494
Pharmigene Inc is engaged in the development and sales of pharmaceutical genetic diagnostic products. Also, the company provides medical and drug testing services and equipment.

Pharmigene (ROCO:7595) Headlines

No Headlines